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HV, especially HBV and HCV, and it seems to be related to the
pathogenicity of cirrhosis and fulminant hepatic failure.
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patients with chronic hepatitis B
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Objectives: We determined whether serum concentration
of TIMP-1 and TIMP-2 are related to the progress of liver
ﬁbrosis in patients with chronic hepatitis B (CHB).
Methods: Commercially available ELISA were used to
study circulating values of TIMP-1 and TIMP-2 in
CHB patients (n = 159) and 20 healthy controls. TIMP-1
and TIMP-2 expressions in the liver were detected
by immunohistochemical staining, then analyzed the
correlation between the levels of hepatic expression
and serum concentration of them. Hepatic histology was
evaluated, and quantiﬁed the stage of ﬁbrosis by using the
Hepatitis-Activity-Index (HAI) according to Ishak et al.
Results: The serum concentration of TIMP-1 or TMIP-2
positively correlated with their expression in the liver
of CHB patients, and both of them were higher in
the patients than those in the healthy controls, and
which had a signiﬁcant difference (P < 0.05). The serum
concentrations of TIMP-1 and TIMP-2 increased signiﬁcantly
with development of ﬁbrosis and had positive correlations
with HAI (r = 0.51, P < 0.01; r = 0.42, P < 0.01), whereas serum
ALT wasn’t related to ﬁbrosis or HAI.
Conclusions: Regular determinations of both TIMP-1 and
TIMP-2 in CHB patients may be used as indicators of
increasing ﬁbrosis.
Figure 1. Correlation between TIMP-1 and -2 expressions in
the liver and their concentration in the serum of patients
with CHB.
Table 1. The serum concentration of TIMP-1 and -2 in CHB patients with
different stages of ﬁbrosis
TIMP-1 (mg/L) TIMP-2 (mg/L) ALT (IU/L)
S0 84.32±18.53 52.34±24.21 45.37±9.31
S1 109.32±14.67 108.96±12.56 105.54±8.59
S2 135.65±22.95 111.47±25.32 676.4±202.35
S3 181.05±39.44 178.28±17.76 432.2±273.88
S4 279.91±61.83 255.54±110.02 75.7±29.80
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Introduction: Hepatitis B virus infection is recognized as
a major public health problem causing acute, persistant
or chronic liver infection. In Egypt, hepatitis B virus
infection is considered to be endemic. The attack rate of
hepatitis B was estimated to reach 8.9/10,000 in Alexandria.
Schistosomiasis is considered the major health problem in
Egypt. 12 14 million people are infected with Schistosoma
mansoni.
When Schistosomal and non-Schistosomal patients were
exposed to HBV, they were found to be equally susceptible,
however follow-up studies claimed that the ﬁrst group of
patients tend to exhibit hepatitis B antigenemia for longer
periods than the second group and this may hugely increase
the reservoir of carriers.
Aim: Determine the prevalence of HBsAg carriers,
demonstration of routes of antigen excretion and its
presence in liver sections and the prevalent subtype.
Subjects and Methods: Forty carriers of the hepatitis B
surface antigen were selected from 539 cases of
Schistosomal hepatic ﬁbrosis:
A. Detection of HBsAg in patients sera, Saliva, Urine and
Stools & Anti-HBcAg IgM.
B. Demonstration of HBsAg in infected hepatocytes.
C. Subtyping of HBsAg using the counter immuno-
electrophoresis.
Results:
• Hepatitis B surface antigen carriers was7.42%, Anti-HBsAg
IgM was negative.
• 5% of the salivary samples were HBsAg positive, while 50%
of the Urine and Stool were HBsAg positive.
• Urine and Saliva positivity ran parallel.
• Stool samples positive for HBsAg were all positive for
occult blood.
• Subtyping of the HBsAg for showed the “ay” subspeciﬁcity
which is considered the constant type of North Africa.
Conclusions:
• Screening of Schistosomal patients for the HBs antigen is
of importance as they represent a highly disseminating
source of infection.
• “ay” is the predominant subtype of HBs Ag.
• Disinfection of secretions and excretions of HBsAg positive
patients and their utensils is essential.
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Aims: To evaluate the predictive value of baseline levels of
HBVDNA and ALT for the long term efﬁcacy of lamivudine
treatment for patients with chronic hepatitis B and
determine the optimal cut off values of baseline levels
of HBVDNA and ALT.
Methods: A total of 163 HBeAg-positive chronic hepatitis B
patients receiving LAM treatment were recruited into the
present study. Logistic regression analysis was performed
to screen independent predictors of 2-year on-treatment
virological response among the baseline parameters. The
ROC curve was used to evaluate the predictive value of
these independent predictors. The accuracy of prediction
was assessed using area under curve (AUC) and optimal cut
off values were determined through maximizing Youden’s
index.
Results: After 2 years of LAM treatment, HBVDNA was
undetectable in 114 (69.9%) patients and LAM related
resistance mutation was detectable in 45 (27.6%) patients.
Logistic regression analysis indicated the baseline levels
of ALT and HBVDNA were the independent predictors
